VeraLight’s Scout Eliminates Fasting From Diabetes Screening
This article was originally published in The Gray Sheet
Executive Summary
VeraLight expects to support a de novo 510(k) application for its Scout diabetes screening technology with a trial demonstrating the test's superiority to fasting plasma glucose (FPG) screening, according to CEO David Van Avermaete
You may also be interested in...
Financings In Brief
Tornier majority stake goes to investor group: French orthopedic device maker Tornier is majority owned by private equity investor Warburg Pincus and venture capital firm The Vertical Group under a transaction announced July 18. The Grenoble, France-based company's joint replacement offerings include hips, knees, shoulders, ankles and other extremity prostheses. Terms of the deal were not disclosed. Similarly, orthopedic device firm Encore Medical recently was bought out by private investment firm Blackstone Capital Partners (1"The Gray Sheet" July 10, 2006, p. 9). In conjunction with the Tornier investment deal, President and CEO Alain Tornier steps down to become chairman as Douglas Kohrs takes over as president and CEO. Kohrs served in the same positions at American Medical Systems from 1999 until 2005, and as chairman from 2004 until 2006...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”